Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "University"

706 News Found

Finerenone hits major goal in Phase III FIND-CKD trial
Clinical Trials | March 16, 2026

Finerenone hits major goal in Phase III FIND-CKD trial

There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk


Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases
Clinical Trials | March 14, 2026

Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases

The early-stage study will test the drug’s safety, tolerability and biological effects in humans


Citius Oncology reports promising early trial results for therapy for gynecologic cancers
Clinical Trials | March 14, 2026

Citius Oncology reports promising early trial results for therapy for gynecologic cancers

The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR


Alcon launches Hydrus Microstent in India to transform glaucoma care
News | March 11, 2026

Alcon launches Hydrus Microstent in India to transform glaucoma care

The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes


Cirena licenses breakthrough RNA synthesis technology from CU Boulder
Biotech | March 11, 2026

Cirena licenses breakthrough RNA synthesis technology from CU Boulder

The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands


Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development
News | March 10, 2026

Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development

The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications


KIMS Hospitals makes bold entry into Bengaluru with two new super-speciality units
Hospitals | March 10, 2026

KIMS Hospitals makes bold entry into Bengaluru with two new super-speciality units

The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management


FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis
Drug Approval | March 10, 2026

FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials


Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy
Clinical Trials | March 10, 2026

Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy

The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen